Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.60 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.45 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642969 | 0.86 | IRAK4 (0.54) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL12392411 | 0.85 | DYRK3 (0.57) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL6641901 | 0.85 | RAB9A (0.52) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL6640662 | 0.84 | IRAK4 (0.50) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL6641452 | 0.84 | IRAK4 (0.52) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL6645137 | 0.84 | RAB9A (0.44) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL6645048 | 0.83 | LMNA (0.45) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL6642610 | 0.82 | FGFR1 (0.55) | LMNAHTTSMN1; SMN2MAP4K4CLK2 | |
| SCHEMBL6642574 | 0.82 | IRAK4 (0.50) | RAB9ALMNARXFP1IRAK4NOD2 | |
| SCHEMBL6646758 | 0.81 | IRAK4 (0.49) | RAB9ALMNARXFP1IRAK4NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1018514-B1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-05-12 | — | — | EP | claimed |
| US-6734180-B1 | NF-κB inhibitor comprising an indan derivative as an active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-05-11 | — | — | US | claimed |
| EP-1018514-A1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2000-07-12 | — | — | EP | claimed |
| EP-2320904-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010030757-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030757-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1018514-B1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6734180-B1 | NF-κB inhibitor comprising an indan derivative as an active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-05-11 | — | — | US | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1018514-A1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | RAB9A 2578/4885LMNA 4824/4885RXFP1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.